Trial record 12 of 42 for:
"Fragile X syndrome"
Safety and Efficacy Study of Antioxidants for the Treatment of the Fragile X Syndrome (SXF-TRA152)
The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2010 by The Mediterranean Institute for the Advance of Biotechnology and Health Research.
Recruitment status was Active, not recruiting
Recruitment status was Active, not recruiting
Sponsor:
The Mediterranean Institute for the Advance of Biotechnology and Health Research
Information provided by:
The Mediterranean Institute for the Advance of Biotechnology and Health Research
ClinicalTrials.gov Identifier:
NCT01329770
First received: March 29, 2011
Last updated: April 5, 2011
Last verified: November 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The Fragile X syndrome (FXS) was first described by Dr. Martin and Dr. Bell in 1943, in families with several patients affected by sex-linked mental disability. This disorder is the most common cause of inherited mental disability. The prevalence of the Fragile X syndrome has been established at 1 in 2,500 males and 1 in 4000 females.
Despite moderate to severe mental retardation, fragile X patients exhibit macroorchidism, an elongated face, long ears, connective tissue dysplasia, hyperactivity, autistic-like and stereotypical behaviours, speech delay and increased sensory sensitivity.
Objective: To evaluate the effect of the combination of the antioxidant Ascorbic acid and tocopherol, as therapy of the Fragile X Syndrome in young males.
Hypothesis: It is proposed that part of the pathophysiology of the central nervous system in the animal model of the fragile X syndrome may be determined by oxidative stress. In addition, Fragile X patients showed a significantly low level of ascorbic acid in plasma. The biochemical characteristics of oxidative stress may be reversed in the FMR1-KO mice, by a chronic treatment with antioxidant compounds such as tocopherol or melatonin, it may also normalize several hallmarks of the Syndrome such as hyperactivity, anxiety and cognitive deficits. The normalization of the oxidative stress is proposed as a new therapeutic pathway to alleviate conditions caused by an excess of free radicals that are crucial in neurodevelopmental diseases such as autism, down syndrome and other diseases of the central nervous system.
| Condition | Intervention | Phase |
|---|---|---|
|
Fragile X Syndrome |
Dietary Supplement: Ascorbic Acid (Vitamin C) and Alpha-tocopherol (Vitamin E) Other: Placebo |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Crossover Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Phase II Double-blind Randomized Placebo-controlled 1-way Crossover Trial to Investigate Safety and Efficacy of the Ascorbic Acid and Tocopherol for the Treatment of the Fragile X Syndrome |
Resource links provided by NLM:
Genetics Home Reference related topics:
fragile X syndrome
MECP2 duplication syndrome
PPM-X syndrome
Renpenning syndrome
tetrasomy 18p
Drug Information available for:
Ascorbic acid
alpha-Tocopherol
Sodium ascorbate
Tocopherol
Vitamin E succinate
Tocopherol acetate
dl-alpha-Tocopherol
U.S. FDA Resources
Further study details as provided by The Mediterranean Institute for the Advance of Biotechnology and Health Research:
Primary Outcome Measures:
- Changes in the baseline Conner's Parent and Teacher Scales at 12 and 24 weeks [ Time Frame: Baseline, week 12, week 24 ] [ Designated as safety issue: No ]Hyperactivity scales: Conners Parent and Teacher Questionnaire, realized before starting treatment, 12 weeks and 24 weeks after beginning the treament.
Secondary Outcome Measures:
- Change in the baseline measure of the Inventory of behaviour development (DBC-P24) at 12 and 24 weeks [ Time Frame: Baseline, week 12 and week 24 ] [ Designated as safety issue: No ]Inventory of behaviour development (DBC-P24) will be realized before starting, 12 weeks and 24 weeks after beginning the treatment
- Wechsler Intelligence Scale for children [ Time Frame: baseline, week 12 and week 24 ] [ Designated as safety issue: No ]Wechsler Intelligence Scale for children will be used at base line and 12 weeks after beginning the treatment
- Safety Evaluation [ Time Frame: Baseline, week 12 and week 24 ] [ Designated as safety issue: Yes ]
Safety Evaluation through blood and urine measurement. The following studies will be done at base line, 12 and 24 weeks after beginnig the treatment:
- Hematology
- Biochemical
- Determination of adrenal axis.
- Oxidative status.
- Analysis of urine density, pH, protein, glucose, ketone bodies, bilirubin, blood, nitrite, urobilinogen, leukocytes, urinary sediment, sodium, chlorine, potassium.
| Enrollment: | 30 |
| Study Start Date: | December 2010 |
| Estimated Study Completion Date: | June 2011 |
| Estimated Primary Completion Date: | March 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Ascorbic Acid and alpha-tocopherol
Two daily doses of the combination of antioxidants, administered at breakfast and dinner
|
Dietary Supplement: Ascorbic Acid (Vitamin C) and Alpha-tocopherol (Vitamin E)
|
|
Placebo Comparator: Placebo
Two daily doses of placebo, administered at breakfast and dinner
|
Other: Placebo
Two daily dose of placebo, administered at breakfast and dinner for 12 weeks
|
Detailed Description:
- Objective: To evaluate the effect of the combination of the antioxidant Ascorbic acid and tocopherol, as therapy of the Fragile X Syndrome in young males.
- Design: Pilot clinical trial, Phase II , 6-month randomized, double-blind placebo-controlled one-way crossover clinical trial, with two treatment periods of 12 weeks duration.
- Setting: IMABIS Foundation. Carlos Haya Hospital, Malaga.
- Subjects: Children aged 5-11 years (infants) and 12-18 years (adolescents) diagnosed with Fragile X syndrome.
- Intervention: 30 participants randomly assigned, to receive antioxidant vitamins C (ascorbic acid) and vitamin E (d-alpha-tocopherol) once a day or placebo for 12 weeks double-blind. In Study Period 2, all participants receive (open) active treatment. Outcome measures: improvement in plasma antioxidant levels, oxidative stress (indicated by glutathione status, thiobarbituric acid reacting substances (TBARS) and carbonyl content of proteins) and HPA axis response. Behavioral problems will be studied using "Developmental behavior checklist" and "Teacher`s and Parent´s Questionnaire, C. Keith Conners", also learning improvement will be analyzed using "Wechsler Intelligence Scale for children" at 0, 3, 6 months during the trial and 3 months after completing the treatment.
Eligibility| Ages Eligible for Study: | 6 Years to 18 Years |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Molecular genetics diagnosis of the syndrome (number of CGG repeats in the FMR1 gene over 200).
- Presenting characteristic symptoms of fragile X syndrome.
- Patients older than 6 years and younger that 19 years.
- Signed informed consent by parents and/or legal tutor prior to enrolment in the trial.
- Both parents and patients must commit to participate for the duration of the 30 week trial.
Exclusion Criteria:
- The study excludes individuals with other neurological disorders not linked to the syndrome.
- Patients that have had serious medical problems in the previous 12 months.
- Are taking more than 100mg of vitamin E or vitamin C daily for the past 4 months.
- Have physical problems, mental or sensory impairments that preclude the assessment of effectiveness.
- Hypersensitivity to any component of the preparation.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01329770
Locations
| Spain | |
| Psychiatric Service. Hospital Carlos Haya | |
| Malaga, Spain, 29009 | |
Sponsors and Collaborators
The Mediterranean Institute for the Advance of Biotechnology and Health Research
Investigators
| Principal Investigator: | Yolanda de Diego Otero, PhD | IMABIS Foundation. Hospital Carlos Haya. Malaga |
| Principal Investigator: | Lucia M Perez Costillas, MD PhD | Hospital Carlos Haya. Malaga |
More Information
Additional Information:
Publications:
| Responsible Party: | Yolanda de Diego Otero PhD, The Mediterranean Institute for the Advance of Biotechnology and Health Research (IMABIS Foundation) |
| ClinicalTrials.gov Identifier: | NCT01329770 History of Changes |
| Other Study ID Numbers: | 2009-017837-23 |
| Study First Received: | March 29, 2011 |
| Last Updated: | April 5, 2011 |
| Health Authority: | Spain: Spanish Agency of Medicines |
Keywords provided by The Mediterranean Institute for the Advance of Biotechnology and Health Research:
|
Neurodevelopmental disability Hyperactivity Anxiety Cognitive problems |
Behavioural symptoms Fragile X syndrome Autism inherited Genetic condition |
Additional relevant MeSH terms:
|
Fragile X Syndrome Mental Retardation, X-Linked Mental Retardation Neurobehavioral Manifestations Neurologic Manifestations Nervous System Diseases Sex Chromosome Disorders Chromosome Disorders Congenital Abnormalities Genetic Diseases, Inborn Genetic Diseases, X-Linked Heredodegenerative Disorders, Nervous System Antioxidants |
Ascorbic Acid Vitamin E Alpha-Tocopherol Tocopherols Tocotrienols Vitamins Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Protective Agents Physiological Effects of Drugs Micronutrients Growth Substances |
ClinicalTrials.gov processed this record on May 23, 2013